PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells
Xinru Wei(China Energy Engineering Corporation (China)), Peng Li(Chinese Academy of Sciences), Baiheng Li(Chinese Academy of Sciences), Duanqing Pei(Westlake University), Yunxin Lai(First Affiliated Hospital of Guangzhou Medical University), Suna Wang(Liaocheng University), Qiting Wu(Chinese Academy of Sciences), Yangqiu Li(Jinan University), Muyun Peng(Central South University), Ruocong Zhao(Chinese Academy of Sciences), Fenglei Yu(Central South University), Yao Yao(Dalian Medical University), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Jin Li(Sichuan University), Simiao Lin(Chinese Academy of Sciences), Le Qin(Shanghai Jiao Tong University), Youdi Xu(Chinese Academy of Sciences), Qiubin Liang(Guangzhou Institutes of Biomedicine and Health), Xuchao Zhang(Guangdong General Hospital), Pentao Liu(Hong Kong Science and Technology Parks Corporation)
Cited by 142
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k